TY - JOUR
T1 - Development of the AI-Cirrhosis-ECG Score
T2 - An Electrocardiogram-Based Deep Learning Model in Cirrhosis
AU - Ahn, Joseph C.
AU - Attia, Zachi I.
AU - Rattan, Puru
AU - Mullan, Aidan F.
AU - Buryska, Seth
AU - Allen, Alina M.
AU - Kamath, Patrick S.
AU - Friedman, Paul A.
AU - Shah, Vijay H.
AU - Noseworthy, Peter A.
AU - Simonetto, Douglas A.
N1 - Funding Information:
Potential competing interests: D.A.S. and V.H.S.'s research are funded by National Institute of Health U01AA026886-03. No other potential conflicts of interest relevant to this article exist. Study Highlights WHAT IS KNOWN
Publisher Copyright:
© 2022 Wolters Kluwer Health. All rights reserved.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - INTRODUCTION:Cirrhosis is associated with cardiac dysfunction and distinct electrocardiogram (ECG) abnormalities. This study aimed to develop a proof-of-concept deep learning-based artificial intelligence (AI) model that could detect cirrhosis-related signals on ECG and generate an AI-Cirrhosis-ECG (ACE) score that would correlate with disease severity.METHODS:A review of Mayo Clinic's electronic health records identified 5,212 patients with advanced cirrhosis ≥18 years who underwent liver transplantation at the 3 Mayo Clinic transplant centers between 1988 and 2019. The patients were matched by age and sex in a 1:4 ratio to controls without liver disease and then divided into training, validation, and test sets using a 70%-10%-20% split. The primary outcome was the performance of the model in distinguishing patients with cirrhosis from controls using their ECGs. In addition, the association between the ACE score and the severity of patients' liver disease was assessed.RESULTS:The model's area under the curve in the test set was 0.908 with 84.9% sensitivity and 83.2% specificity, and this performance remained consistent after additional matching for medical comorbidities. Significant elevations in the ACE scores were seen with increasing model for end-stage liver disease-sodium score. Longitudinal trends in the ACE scores before and after liver transplantation mirrored the progression and resolution of liver disease.DISCUSSION:The ACE score, a deep learning model, can accurately discriminate ECGs from patients with and without cirrhosis. This novel relationship between AI-enabled ECG analysis and cirrhosis holds promise as the basis for future low-cost tools and applications in the care of patients with liver disease.
AB - INTRODUCTION:Cirrhosis is associated with cardiac dysfunction and distinct electrocardiogram (ECG) abnormalities. This study aimed to develop a proof-of-concept deep learning-based artificial intelligence (AI) model that could detect cirrhosis-related signals on ECG and generate an AI-Cirrhosis-ECG (ACE) score that would correlate with disease severity.METHODS:A review of Mayo Clinic's electronic health records identified 5,212 patients with advanced cirrhosis ≥18 years who underwent liver transplantation at the 3 Mayo Clinic transplant centers between 1988 and 2019. The patients were matched by age and sex in a 1:4 ratio to controls without liver disease and then divided into training, validation, and test sets using a 70%-10%-20% split. The primary outcome was the performance of the model in distinguishing patients with cirrhosis from controls using their ECGs. In addition, the association between the ACE score and the severity of patients' liver disease was assessed.RESULTS:The model's area under the curve in the test set was 0.908 with 84.9% sensitivity and 83.2% specificity, and this performance remained consistent after additional matching for medical comorbidities. Significant elevations in the ACE scores were seen with increasing model for end-stage liver disease-sodium score. Longitudinal trends in the ACE scores before and after liver transplantation mirrored the progression and resolution of liver disease.DISCUSSION:The ACE score, a deep learning model, can accurately discriminate ECGs from patients with and without cirrhosis. This novel relationship between AI-enabled ECG analysis and cirrhosis holds promise as the basis for future low-cost tools and applications in the care of patients with liver disease.
UR - http://www.scopus.com/inward/record.url?scp=85123909615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123909615&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000001617
DO - 10.14309/ajg.0000000000001617
M3 - Review article
C2 - 35029163
AN - SCOPUS:85123909615
SN - 0002-9270
VL - 117
SP - 424
EP - 432
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 3
ER -